You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

Taro Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Taro
International Patents:31
US Patents:8
Tradenames:134
Ingredients:117
NDAs:255
Patent Litigation for Taro: See patent lawsuits for Taro
PTAB Cases with Taro as petitioner: See PTAB cases with Taro as petitioner

Drugs and US Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds AMCINONIDE amcinonide CREAM;TOPICAL 076229-001 May 31, 2002 AB RX No No ⤷  Sign Up ⤷  Sign Up
Taro IBUPROFEN ibuprofen SUSPENSION;ORAL 209207-001 Jun 27, 2017 OTC No No ⤷  Sign Up ⤷  Sign Up
Taro CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES fexofenadine hydrochloride SUSPENSION;ORAL 208123-002 Nov 9, 2017 OTC No No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Taro

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-001 Jan 17, 2008 6,656,482 ⤷  Sign Up
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 6,102,254 ⤷  Sign Up
Taro FLO-PRED prednisolone acetate SUSPENSION;ORAL 022067-002 Jan 17, 2008 6,399,079 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TARO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18

Supplementary Protection Certificates for Taro Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 122012000070 Germany ⤷  Sign Up PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
2932970 SPC/GB18/041 United Kingdom ⤷  Sign Up PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518
2203431 15C0013 France ⤷  Sign Up PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.